InspireMD, Inc. reported its financial results for the third quarter ended September 30, 2024, on November 12, 2024. The company announced total revenue of $1.81 million, marking a 16.3% increase compared to the third quarter of 2023.
Despite the revenue growth, the net loss for the quarter was $0.16 per basic and diluted share, compared to a net loss of $0.15 per share in the prior year period. This widening loss was primarily driven by increased operating expenses as the company invested in U.S. launch preparations and pipeline development.
Key business highlights included the submission of the Premarket Approval (PMA) application to the FDA for the CGuard Prime carotid stent system and the approval of an IDE application for the CGUARDIANS II pivotal study. The company also established its headquarters in Miami, Florida, to support the anticipated U.S. commercial launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.